Castle Biosciences (NASDAQ:CSTL) Insider Sells $483,594.50 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 18,650 shares of Castle Biosciences stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $25.93, for a total transaction of $483,594.50. Following the transaction, the insider directly owned 22,129 shares of the company’s stock, valued at approximately $573,804.97. This trade represents a 45.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Castle Biosciences Price Performance

Shares of CSTL opened at $25.00 on Friday. The company’s 50-day moving average is $33.22 and its 200-day moving average is $31.75. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.26 and a quick ratio of 5.11. The firm has a market capitalization of $743.25 million, a PE ratio of -29.41 and a beta of 1.09. Castle Biosciences, Inc. has a fifty-two week low of $14.59 and a fifty-two week high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last announced its earnings results on Thursday, February 26th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.15. Castle Biosciences had a negative net margin of 7.02% and a negative return on equity of 0.89%. The business had revenue of $81.88 million during the quarter, compared to the consensus estimate of $81.19 million. Equities analysts forecast that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Canaccord Genuity Group boosted their price objective on Castle Biosciences from $37.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. Lake Street Capital lifted their price target on Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, January 12th. KeyCorp restated an “overweight” rating and issued a $50.00 price target on shares of Castle Biosciences in a research note on Thursday, January 29th. Guggenheim upped their price objective on Castle Biosciences from $43.00 to $47.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, Morgan Stanley upgraded Castle Biosciences to a “buy” rating in a research report on Monday, March 2nd. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.57.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. bought a new stake in shares of Castle Biosciences in the fourth quarter valued at approximately $26,000. Farther Finance Advisors LLC increased its stake in Castle Biosciences by 139,100.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock worth $32,000 after acquiring an additional 1,391 shares during the period. State of Alaska Department of Revenue acquired a new position in Castle Biosciences in the 3rd quarter valued at $35,000. Kemnay Advisory Services Inc. acquired a new position in Castle Biosciences in the 4th quarter valued at $35,000. Finally, CWM LLC lifted its position in shares of Castle Biosciences by 80.6% during the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock valued at $44,000 after acquiring an additional 853 shares during the period. 92.60% of the stock is owned by institutional investors.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.